



an Open Access Journal by MDPI

Advancements in Synthetic Small Molecules as Anti-cancer Therapeutics

Guest Editors:

Dr. Amandeep Singh

Department of Pharmacology,
College of Medicine, Penn State
University, Hershey, PA 17033,
USA

Dr. Harbinder Singh

Department of Biological
Sciences, University of Toledo,
Toledo, OH 43606, USA

Dr. Anu Rani

Department of Chemistry,
Washington State University,
Pullman, WA 99164, USA

Deadline for manuscript
submissions:

closed (30 June 2024)

Message from the Guest Editors

Dear Colleagues,

Cancer is the uncontrolled, rapid, and pathological proliferation of abnormal cells, which is a tremendous problem worldwide today. According to the World Health Organization (WHO), cancer is the second leading cause of death globally. Its treatment remains challenging for the scientific community. One major problem with its treatment is that most of the currently available drugs are unable to differentiate between normal and abnormal cells, which is the reason behind their side effects such as thrombocytopenia, anemia, delirium, edema, etc. Anticancer small molecules, also known as small molecule inhibitors, are a type of therapeutic agent used in cancer treatment. These molecules are small organic compounds that can penetrate cells and interact with specific targets involved in cancer cell growth and survival. They work by inhibiting or interfering with the activity of proteins or pathways that are essential for cancer cell proliferation. This Special Issue welcomes research and up-to-date review articles addressing current research on anticancer therapeutics, with a particular focus on discovering novel anti-cancer small molecules.



mdpi.com/si/178174

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI